Bayer Animal Health has launched Veraflox (pradofloxacin), a next generation fluoroquinolone antimicrobial with an enhanced spectrum of activity, for the treatment of bacterial infections in cats and dogs.

Bayer Animal Health has launched Veraflox (pradofloxacin), a next generation fluoroquinolone antimicrobial with an enhanced spectrum of activity, for the treatment of bacterial infections in cats and dogs.

The product is also the first fluoroquinolone to be used in periodontal infections in dogs.

Bayer Animal Health’s marketing manager Dr Markus Edingloh explained: “Veraflox, with its molecular compound pradofloxacin, developed exclusively for veterinary medicine, marks a major leap forward in veterinary antibiotic therapy and patient care.

“Veraflox has an enhanced spectrum of antimicrobial activity which encompasses Gram-positive and anaerobic bacteria. In addition, Veraflox has demonstrated high levels of bactericidal activity against target pathogens, including activity against dormant bacteria typically found in chronic infections.”

A new generation fluoroquinolone antimicrobial for cats and dogs called Veraflox (pradofloxacin) has been launched by Bayer Animal Health.For cats, a specially formulated oral suspension is available in which a fine-grained ion exchange agent binds to the antibiotic, allowing it to pass the cat’s taste buds undetected. Veraflox oral suspension is indicated for the treatment of upper respiratory tract infections, wound infections and abscesses. The 15mg tablet is also licensed in cats for treating upper respiratory tract infections.

In dogs, in addition to its other indications, Veraflox is said to be “very effective” at combatting anaerobic bacteria that play a major role in aggressive bone destruction in periodontal disease.

Veraflox is the first fluoroquinolone to be licensed in dogs for the adjunctive treatment of severe infections of the gingiva and periodontal tissues. However, in addition to its dental claims for dogs, it is also indicated for the treatment of wound infections, superficial and deep pyoderma, and acute urinary tract infections. It is available as a once-daily flavoured tablet.

Dr Edingloh said: “The unique chemistry and way in which Veraflox works gives it superior antibacterial activity compared with existing fluoroquinolones […] Veraflox provides vets with more predictability, reliability and peace of mind, especially in difficult to treat infections.”

Companion animal vets wanting to learn more about Veraflox can sign up to a free webinar featuring lectures by leading dermatology and microbiology experts, as well as a review of the features and characteristics of the product and results of clinical studies.
 
This free one-hour webinar can be watched live on October 25 at 7:30pm and will offer the opportunity to put questions to the speakers. A recording of the event can be viewed afterwards.

 

    View your activity >

    Leave a Reply

    Be the First to Comment!

    Notify of
    avatar

    wpDiscuz